Dr. Reddy’s announces strategic alliance with GSK for Emerging Markets

June 15, 2009 - PRLog -- • Partnership covers Generics and Differentiated Formulations

June 15, 2009, Hyderabad

Dr. Reddy’s Laboratories  today announced a partnership with GlaxoSmithKline plc (GSK) to develop and market select products across emerging markets outside India.

Under the terms of the agreement, which is effective immediately, GSK will gain access to Dr. Reddy’s rich and diverse portfolio and future pipeline of more than 100 branded pharmaceuticals in fast growing therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.

For further details visit: www.drreddys.com

# # #

Established in 1984, Dr. Reddy’s Laboratories  is an emerging global pharmaceutical company. As a fully integrated pharmaceutical company, our purpose is to provide affordable and innovative medicines through our three core businesses:
Pharmaceutical Services and Active Ingredients, comprising our Active Pharmaceuticals and Custom Pharmaceuticals businesses; Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), Differentiated Formulations, and Generic Biopharmaceuticals. Our products are marketed globally, with a focus on India, US, Europe and Russia. Dr. Reddy’s conducts NCE research in the areas of metabolic disorders, cardiovascular indications, anti-infectives and inflammation.